Clinical trials: Advanced Solid Tumor Malignancies
Advanced Solid Tumor
A Phase I/II Study of HY05350 in Mesothelin(MSLN)-Positive Advanced Solid Tumors
This is a multicenter, open-label Phase I/II clinical study to evaluate the safety, tolerability, pharmacokinetic characteristics and preliminary clinical efficacy of HY05350 for injection in patients with MSLN-positive advanced…
- Trial name
- NCT07083323
- Testing
- HY05350 for injection
- Where
- China
- Volunteers
- 262 people, healthy volunteers welcome
- Sponsor
- Sichuan Huiyu Pharmaceutical Co., Ltd
Advanced Solid Tumors, Undifferentiated Pleomorphic Sarcoma
ABBV-085, an Antibody Drug Conjugate, in Subjects With Advanced Solid Tumors
This is an open-label dose escalation study designed to evaluate the safety and pharmacokinetics of ABBV-085 and determine the recommended Phase 2 dose (as monotherapy or in combination with standard therapies) in subjects with…
- Conditions
- Advanced Solid Tumors, Undifferentiated Pleomorphic Sarcoma, Squamous Cell Carcinoma of the Head and Neck, Carcinoma of the Breast
- Trial name
- NCT02565758
- Testing
- ABBV-085
- Where
- 20 sites in United States, France and 1 more
- Volunteers
- 85 people
- Sponsor
- AbbVie
Gastrointestinal Tumor
A Study of BL-B01D1 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumor and Other Solid Tumor
In phase Ia study, the safety and tolerability of BL-B01D1 in patients with locally advanced or metastatic gastrointestinal tumor and other solid tumor will be investigated to determine the dose-limiting toxicity (DLT), maximum…
- Trial name
- NCT05262491
- Testing
- BL-B01D1
- Where
- 6 sites in China
- Volunteers
- 96 people
- Sponsor
- Sichuan Baili Pharmaceutical Co., Ltd.
Nasopharyngeal Neoplasms
Safety and Efficacy of CC-486 in Previously Treated Patients With Locally Advanced or Metastatic Nasopharyngeal Carcinoma
The purpose of this study is to evaluate the safety and efficacy of CC-486 in previously treated patients with locally advanced or metastatic nasopharyngeal carcinoma having failed one to two previous regimens, including…
- Trial name
- NCT02269943
- Testing
- CC-486
- Where
- 25 sites in United States, Canada and 7 more
- Volunteers
- 36 people
- Sponsor
- Celgene
Solid Tumors
Phase 1 Study of IBR854 in Locally Advanced Or Metastatic Solid Tumors
This study is an open-label, phase I study to evaluate the safety, tolerability, pharmacokinetics (PK), and preliminary efficacy of IBR854 cell injection in patients with unresectable, locally advanced, or metastatic solid tumors.
- Trial name
- NCT06001684
- Testing
- IBR854 Cell Injection
- Where
- China
- Volunteers
- 19 people
- Sponsor
- Imbioray (Hangzhou) Biomedicine Co., Ltd.
Gastric or Gastro-esophageal Junction (GEJ) Adenocarcinoma, Pancreatic Adenocarcinoma
A Study of ASP546C in Adults With Gastroesophageal Cancer, Pancreatic Cancer or Other Solid Tumors
This study will help find the most suitable dose of ASP546C in people with gastric cancer, gastroesophageal junction (GEJ) cancer, pancreatic cancer, and other specific solid tumors.
- Trial name
- NCT07488676
- Testing
- ASP546C
- Where
- 21 sites in United States, Japan
- Volunteers
- 150 people
- Sponsor
- Astellas Pharma Global Development, Inc.
Relapsed Small Cell Lung Cancer
Safety and Tolerability Evaluation of Low-dose Radiation in Combination With CS1001 in Relapsed SCLC Patients
A Phase Ia/Ib Safety and Tolerability Evaluation of Low-dose Radiation in Combination with CS1001 in relapsed SCLC patients
- Trial name
- NCT04421352
- Testing
- CS1001
- Where
- China
- Volunteers
- 11 people
- Sponsor
- CStone Pharmaceuticals
Advanced Solid Tumor, Advanced or Metastatic Non-small Cell Lung Cancer
Phase I Study of the BBP-398 in Patients With Advance Solid Tumors
This is an open label, dose escalation and expansion, two-part Phase I study for SHP-2 inhibitor BBP-398 to evaluate the safety, tolerability, pharmacokinetics, determine MTD and/or RP2D, and preliminary anti- cancer activity in…
- Trial name
- NCT05621525
- Testing
- BBP-398
- Where
- 2 sites in China
- Volunteers
- 7 people
- Sponsor
- LianBio LLC
Advanced Solid Tumor
A Phase I/IIa Study of JAB-23E73 in Patients With Advanced Solid Tumors Harboring KRAS Gene Alteration
This is a multicenter, open-label, phase I/IIa to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics, and preliminary antitumor activity of pan-KRAS inhibitor JAB-23E73 in patients with advanced solid…
- Trial name
- NCT06959615
- Testing
- JAB-23E73
- Where
- 32 sites in China
- Volunteers
- 334 people
- Sponsor
- Jacobio Pharmaceuticals Co., Ltd.
Breast Cancer, Ovarian Cancer
Phase I Study of Lurbinectedin (PM01183) in Combination With Paclitaxel, With or Without Bevacizumab, in Selected Advanced Solid Tumors
Clinical trial of PM01183 in combination with paclitaxel, with or without bevacizumab, in patients with solid tumors
- Conditions
- Breast Cancer, Ovarian Cancer, Gynecological Cancer, Head and Neck Carcinoma
- Trial name
- NCT01831089
- Testing
- PM01183 + paclitaxel +/- bevacizumab
- Where
- 3 sites in United States, Spain and 1 more
- Volunteers
- 69 people
- Sponsor
- PharmaMar
Advanced Solid Tumors, Acute Myeloid Leukemia
Rollover Study for Subjects Who Have Participated in an Astellas Sponsored ASP2215 Trial
The purpose of the study was to provide access to continued treatment for those who participated in other Astellas sponsored ASP2215 trials that completed the primary analysis and, had the potential to continue to derive clinical…
- Trial name
- NCT02561455
- Testing
- Gilteritinib
- Where
- 7 sites in United States
- Volunteers
- 9 people
- Sponsor
- Astellas Pharma Global Development, Inc.
KRAS Mutant Solid Tumors
TLN-372 in Advanced KRAS Mutant Solid Tumors
The primary purpose of this study is to evaluate the safety, pharmacokinetics, and anti-tumor activity of TLN-372 as a single agent and in combination with other anti-tumor agents, in patients with advanced KRAS mutant solid…
- Trial name
- NCT07204340
- Testing
- TLN-372, TLN-372 in combination with cetuximab, TLN-372 in combination with pembrolizumab
- Where
- 11 sites in United States, Australia and 2 more
- Volunteers
- 270 people
- Sponsor
- Treeline Biosciences, Inc.
Metastasis, Neoplasm
A Phase 1 Study of BPI-28592 in Subjects With Advanced Solid Tumors
This is an open-labe Phase I study of BPI-28592 for the treatment of patients with solid tumors
- Trial name
- NCT05302843
- Testing
- BPI-28592
- Where
- China
- Volunteers
- 40 people
- Sponsor
- Betta Pharmaceuticals Co., Ltd.
Gastrointestinal Stromal Tumors
CGT9486 (Formerly Known as PLX9486) as a Single Agent and in Combination With PLX3397 (Pexidartinib) or Sunitinib in Participants With Advanced Solid Tumors
The goal of this clinical research study is to learn how CGT9486 (fka PLX9486) may affect cancer cells with certain mutations in the KIT gene, specifically in participants with types of advanced solid tumors including…
- Trial name
- NCT02401815
- Testing
- CGT9486, Pexidartinib, Sunitinib
- Where
- 6 sites in United States
- Volunteers
- 51 people
- Sponsor
- Cogent Biosciences, Inc.
Neoplasms, Neoplasm Metastasis
A Dose Escalation With Expansion Study of EMB-01 in Participants With Advanced/Metastatic Solid Tumors
First-in-human, Phase I/II, Multicenter, Open-Label Study of EMB-01 in Patients with Advanced/Metastatic Solid Tumors
- Conditions
- Neoplasms, Neoplasm Metastasis, Non-Small-Cell Lung Cancer
- Trial name
- NCT03797391
- Testing
- EMB-01
- Where
- 5 sites in United States, China
- Volunteers
- 186 people
- Sponsor
- Shanghai EpimAb Biotherapeutics Co., Ltd.
Advanced Solid Tumors
SKB118 Injection in Advanced Solid Tumors
This is a multicenter, open-label, Phase I/II clinical study. The study is divided into two parts, the SKB118 monotherapy study and the SKB118 in combination with SKB264 study.
- Trial name
- NCT07586943
- Testing
- SKB118 Injection, SKB118+SKB264
- Where
- China
- Volunteers
- 530 people
- Sponsor
- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Advanced Solid Tumors
Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetic Profile of XNW7201 in Subjects With Advanced Solid Tumors
The research project is testing this potential new medication for advanced solid tumours. This research project is being done to get more information about the study drug (XNW7201).
- Trial name
- NCT03901950
- Testing
- XNW7201 tablets
- Where
- Australia
- Volunteers
- 45 people
- Sponsor
- Evopoint Biosciences Inc.
Advanced or Metastatic Solid Tumors
A Dose Escalation and Expansion Study of TAC-001 in Patients With Select Advanced or Metastatic Solid Tumors
INCLINE-101 is an open label, multicenter Phase 1/2 study designed to evaluate safety, pharmacokinetics (PK), and preliminary anti-tumor activity of TAC-001 administered intravenously.
- Trial name
- INCLINE-101 (NCT05399654)
- Testing
- TAC-001
- Where
- 12 sites in United States, Australia
- Volunteers
- 72 people
- Sponsor
- Tallac Therapeutics
Advanced Solid Tumor, Advanced Breast Cancer
A Phase 1 Study of BMS-986500 as Monotherapy or Combination Therapy in Advanced Solid Tumors
The purpose of this study is to assess BMS-986500 as monotherapy in advanced solid tumors and as combination therapy in CDK4/6 inhibitor pre-treated advanced breast cancer.
- Conditions
- Advanced Solid Tumor, Advanced Breast Cancer, Advanced Ovarian Cancer
- Trial name
- NCT06997029
- Testing
- BMS-986500, Palbociclib, Fulvestrant
- Where
- 21 sites in United States, Denmark and 1 more
- Volunteers
- 234 people
- Sponsor
- Bristol-Myers Squibb
Advanced Solid Tumor, Metastatic Solid Tumor
Phase I, FIH, MTD for MPT0B640, Multi-centre, Open-label, Subject With Locally Advanced or Metastatic Solid Malignancies
Phase l, First in Human, Multi-centre, Open-label, Clinical Trial of MPT0B640 in Subject with Locally Advanced or Metastatic Solid Malignancies Phase I. Advanced or metastatic solid malignancy First in Human.
- Trial name
- MPT0B64 (NCT04294875)
- Testing
- MPT0B640
- Sponsor
- J Ints Bio
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.